explore -WSS

explore

author：leisure time 2025-09-30 14:10:15 - browse：15143

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： JPM 2024: Nvidia claims we're in biological revolution. Are we?

focus

WSS

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Pharmacists can make shortage drugs, but at what cost?

How I ended up pumping milk in a bathroom stall at JPM 2024

As JPM 2024 winds down, some health tech firms project optimism

hotspot

explore

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

STAT Summit: Biotech founders on deal

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA gives detailed accounting of AI

Sports medicine is finally prioritizing gender equality

New England Journal of Medicine addresses racist history, slavery

After affirmative action ruling, medical educators look to 'holistic review'

New menopause drug shows promise in relief for hot flashes

Medical leaders decry Supreme Court decision on affirmative action

Impact of Dobbs ruling felt at reproductive medicine meeting

focus

Designating disabled people as health disparity population is crucial

Beam Therapeutics to lay off 20% of its staff, re

Pharmacists can make shortage drugs, but at what cost?

Lawmakers consider Medicare pay reforms for doctors

GSK to buy asthma

HHS names first

focus

focus

focus

Wikipedia